Φορτώνει......
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
BACKGROUND: Recently, brentuximab vedotin has become a promising therapeutic approach for CD30-positive hematological malignancies, but its role in other relapsed or refractory malignant lymphoma needs to be proven. Brentuximab vedotin was demonstrated effective, but no study has summarized the conc...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Drug Des Devel Ther |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4408955/ https://ncbi.nlm.nih.gov/pubmed/25945039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83592 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|